Illimis Therapeutics’ Series B round was led by Korean venture capital firm DSC Investment. Seoul-based Illimis Therapeutics ...

Some of the most high-profile acquisitions in recent years have involved women-fronted biotechs. BioSpace reviews five of the ...

Scientists have used an AI model to reassess the results of a completed clinical trial for an Alzheimer's disease drug. They ...

The FDA has updated the labeling for Kisunla™ (donanemab-azbt) to include a new recommended titration dosing schedule for adults with early symptomatic Alzheimer disease.

Background Alexander disease is an autosomal dominant leukodystrophy caused by heterozygous pathogenic variants in the glial ...